AZ compound
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease (NAFLD)
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Trial Timeline
Nov 1, 2015 → Sep 1, 2019
NCT ID
NCT02605616About AZ compound
AZ compound is a phase 2 stage product being developed by AstraZeneca for Non-alcoholic Fatty Liver Disease (NAFLD). The current trial status is terminated. This product is registered under clinical trial identifier NCT02605616. Target conditions include Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02605616 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease (NAFLD)